Home > Boards > US OTC > Biotechs > Hepion Pharmaceuticals, Inc (HEPA)
Followed By 197
Posts 2603
Boards Moderated 0
Alias Born 02/10/2017

Wednesday, June 02, 2021 7:29:01 PM

Re: None

Post# of 1938
4th Global Nash conference HEPA Presentation.
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf


HEPA Lots of potential look for fast tracking on NASH.


Phase 2B Nash trial starts Q3 this year.


No approved drugs for NASH HEPA CRV431 is very safe and efficacy looks very promising.


CEO Foster has brought a blockbuster drug to market in his last company.


For newcomers, Hepion is already moving on to Phase IIb with CRV431 in NASH, based on the low-dose (75mg) results alone, which after 28 days were as good as what Madrigal's P3 lead NASH drug took 12 weeks to achieve.

Having noted that, the higher CRV431 dose (225mg) results are expected to be even far better, with AI-POWR projections shown in slides from this recent presentation Pat Mayo gave at the Global NASH Congress. Take a look at pages 22-25
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf

Also, keep in mind tha HEPAt CRV431 is far and away the best anti-fibrotic in the clinic today. Nothing else compares!


HEPA Another molecule is coming to the pipeline, P2 studies are being planned with CRV431 in multiple myeloma, hepatoma, probably IPF, some anti-viral applications, and so forth, all with enormous potential, based on AI-POWR projections Here's much of what we know about the AI-POWR platform. Development of the platform began in what's called the "AI winter", in the early 1990's, long before others were even thinking about employing AI in drug development. Hepion recently put it into full operation, after nearly thirty years of development, so they are way ahead in this area. The potential cost savings for clinical trials is incalculable!.
https://hepionpharma.com/ai-powr/



MDGL 1.8 Billion market cap Phase 3 results so far look mediocre at best 300 million in cash.

HEPA 130 million market cap Phase 2B commencing soon. 120 million in cash.

$HEPA
Recent HEPA News

FEATURED Emerging Markets Report: A Case for Uranium May 26, 2022 10:07 AM

FEATURED Grove Inc. Upexi Division Launches Medicinal Mushroom Product Line Direct to Consumer and on Amazon May 26, 2022 9:07 AM

FEATURED SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome May 26, 2022 8:35 AM

Thunder Energies Signs $40 Million Funding Agreement TNRG May 26, 2022 4:30 PM

HNRC UPDATES ON SECOND $100 MILLION DOLLAR SPAC HNRC May 26, 2022 10:00 AM

Branded Legacy, Inc. Signs LOI To Acquire First Patent Thomas Pepper Johnson To Join Company's Executive Team BLEG May 26, 2022 8:30 AM

Dalrada Continues Upward Trajectory with 252% Growth in Third Quarter 2022 Financial Results DFCO May 26, 2022 8:00 AM

Atlanta Based Specialty Realty Group Reorganizes, Changes Business Plan & Leadership TNRG May 25, 2022 8:00 PM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Agrees Terms With an Acquisition Delivering Upwards of $100 Million in Annual Revenue ILUS May 25, 2022 11:52 AM

Branded Legacy, Inc. To Introduce New Delta 9 blend THC-0/Delta-8 Blend Gummies Sell Out Again BLEG May 25, 2022 8:30 AM

Goldshore Resources Announces Public (NSERC & MITACS) and Educational (Lakehead University) Tri-Party Institutional Partnership with Alliance Grant GSHR May 25, 2022 8:20 AM

Ultrack Systems Fully Acquires California Trucking Company M-Loan Inc. MJLB May 24, 2022 9:30 AM

SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment CMND May 24, 2022 8:36 AM

PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America PSYC May 24, 2022 8:30 AM

Splash Beverage Group Broadens Reach through Agreement with Maryland's Buck Distributing SBEV May 24, 2022 8:12 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y